

Pandemic Security Initiative: Protecting the Nation from the Next Infectious Disease Threats



The Issue

Pandemics are a clear-and-present danger to life as we know it. They have been with us for thousands of years, they are existential, and we still do not have a solution. Even in the present day, we remain structurally unprepared to combat infectious disease:

- There is no market for diseases without incidence. The standard pharma industry model doesn't work for most infectious diseases — **especially sporadic ones.**
- Without a market to provide returns, there is no investment. Pandemic threat mitigation is almost exclusively a governmental undertaking.

The Solution: Pandemic Security Initiative, a Public-Private Partnership

Unleash American innovation already present in our universities, government labs, and small businesses.

- NIAID is the world's premiere funding source for infectious diseases, providing almost \$6B/y to the best and brightest infectious disease researchers in the country. They are constantly inventing and discovering. They are not, however, equipped to turn an invention into a therapy.
- An entrepreneurial, agile, executive and purpose-built public-private partnership (PPP) with a sharp focus on identifying and developing novel diagnostics, vaccines, prophylactics, and therapeutics would protect the country against pandemic-scale threats.
- **As an operating, drug-developing entity,** this PPP complements and supports BARDA and HHS.
- With development funding from the federal government, pricing of approved innovative medicines will be limited to "cost-plus" (based on CoGS, not development costs).

FAST FACT: INVESTING IN THE U.S. WORKFORCE

The PPP is also an investment in American workers. All research, development, and manufacturing will take place in the U.S.

MISSION

Protect the nation from the next infectious disease threats.

VISION

Within 5 years, we will deliver an arsenal of tests, vaccines, and medicines to secure the nation's health and economy.

Why Celdara

Celdara Medical was purpose-built to transform academic innovations into high-impact medicines. In concert with our affiliates Virtici (Seattle) and MBV (Indianapolis), we already work with hundreds of academic institutions representing over \$10B/year in NIH research funding.

Celdara is the fastest-growing company in the state of New Hampshire (in all sectors, based on 3-year AAGR) for each of the last three years, and has been in the top 10 for each of the last six years, winning accolades from the NIH, SBA, and various federal, state, and local agencies, as well as national and international publications. We have established academic innovation networks worldwide, and "boots on the ground" in Boston, New York, Indianapolis (MBV), and Seattle (Virtici).

Furthermore, we have—with the support of the NIH—established multi-state partnerships to improve medical entrepreneurship in Vermont, New Hampshire, Maine, Rhode Island, and Delaware. Our affiliate Virtici leads a similar effort for Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming. We work with the country's major contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), as well as most major biotech and pharma companies. Universities, pharmaceutical companies, CROs, and CDMOs to date have been **unanimously supportive** of the Pandemic Security Initiative.

The PPP provides financial security for the developer, and pricing security for our government, while creating jobs, securing supply chains, and securing the health and economy for the benefit of all.


Bridging the Gap: Unleashing Innovation for Patient & Societal Benefit

The Pandemic Security Initiative is an integral part of the solution. Scientific funding, research, and innovation processes already work well. In parallel, we must continue the repurposing of drugs developed for other indications, as well as the development of rapid-response platforms.

Scientific funding, research, and innovation processes already work well. However, there is a gap between the invention of new tests, vaccines, and therapies, and our ability to develop and stockpile them. The Pandemic Security Initiative proactively identifies the most promising medical countermeasure innovations, and develops them into approved products to span this crucial gap.

Today, innovation thrives with the support of government-funded research.

However, much of this innovation doesn't reach patients because there is no commercial market for diseases without incidence. A gap in development exists due to the standard pharmaceutical industry model and the lack of market incentive.



Celdara is bridging the gap, building a public-private partnership (PPP) to unleash a pipeline of innovation that is already present in our universities, government labs, and small businesses to protect the country against pandemic-scale threats.

Our Partners

Celdara Medical's academic and research institution partners span America and include:

Representative Universities

- Albert Einstein College of Medicine
- Brown University
- Cedars-Sinai Medical Center
- Cincinnati Children's Hospital
- Columbia University
- Dartmouth College
- Emory University
- Florida State University
- Harvard Medical School
- Indiana University
- Johns Hopkins University
- Maine Medical Center
- Mt. Sinai School of Medicine
- North Carolina State University
- Northwestern University
- The Rockefeller University
- University of Chicago
- University of Delaware
- University of Hawaii
- University of Idaho
- University of Louisville
- University of Montana
- University of Nevada Las Vegas
- University of New Mexico
- University of Pittsburg
- University of Washington
- University of Wisconsin
- Vanderbilt University

Representative Research Institutions

- Brigham and Women's Hospital
- Fred Hutchinson Cancer Research Center
- La Jolla Institute for Immunology
- Massachusetts General Hospital
- Mayo Clinic
- U.S. Army Medical Research Institute of Infectious Diseases